Lin BioScience Statistics
Total Valuation
Lin BioScience has a market cap or net worth of TWD 7.30 billion. The enterprise value is 4.99 billion.
Market Cap | 7.30B |
Enterprise Value | 4.99B |
Important Dates
The next estimated earnings date is Wednesday, November 13, 2024.
Earnings Date | Nov 13, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Lin BioScience has 78.63 million shares outstanding. The number of shares has increased by 6.63% in one year.
Shares Outstanding | 78.63M |
Shares Change (YoY) | +6.63% |
Shares Change (QoQ) | +3.94% |
Owned by Insiders (%) | 1.85% |
Owned by Institutions (%) | 0.12% |
Float | 76.60M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
PB Ratio | 2.88 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -6.82 |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -4.20 |
Financial Position
The company has a current ratio of 32.95, with a Debt / Equity ratio of 0.86.
Current Ratio | 32.95 |
Quick Ratio | 31.70 |
Debt / Equity | 0.86 |
Debt / EBITDA | n/a |
Debt / FCF | -0.03 |
Interest Coverage | -1,141.95 |
Financial Efficiency
Return on equity (ROE) is -37.51% and return on invested capital (ROIC) is -24.71%.
Return on Equity (ROE) | -37.51% |
Return on Assets (ROA) | -23.80% |
Return on Capital (ROIC) | -24.71% |
Revenue Per Employee | n/a |
Profits Per Employee | n/a |
Employee Count | n/a |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -25.20% in the last 52 weeks. The beta is -0.06, so Lin BioScience's price volatility has been lower than the market average.
Beta (5Y) | -0.06 |
52-Week Price Change | -25.20% |
50-Day Moving Average | 99.17 |
200-Day Moving Average | 100.20 |
Relative Strength Index (RSI) | 44.14 |
Average Volume (20 Days) | 185,137 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -1.28B |
Pretax Income | -1.22B |
Net Income | -731.66M |
EBITDA | -1.27B |
EBIT | -1.28B |
Earnings Per Share (EPS) | -9.49 |
Balance Sheet
The company has 4.17 billion in cash and 37.30 million in debt, giving a net cash position of 4.13 billion or 52.50 per share.
Cash & Cash Equivalents | 4.17B |
Total Debt | 37.30M |
Net Cash | 4.13B |
Net Cash Per Share | 52.50 |
Equity (Book Value) | 4.35B |
Book Value Per Share | 32.29 |
Working Capital | 4.20B |
Cash Flow
In the last 12 months, operating cash flow was -1.18 billion and capital expenditures -5.49 million, giving a free cash flow of -1.19 billion.
Operating Cash Flow | -1.18B |
Capital Expenditures | -5.49M |
Free Cash Flow | -1.19B |
FCF Per Share | -15.12 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Lin BioScience does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -6.63% |
Shareholder Yield | -6.63% |
Earnings Yield | -10.22% |
FCF Yield | -16.28% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |